The role of pneumolysin in pneumococcal pneumonia and meningitis

Clinical and Experimental Immunology

Volumn 138, Issue 2, 2004, Pages 195-201

  Hirst, R A ^a   Kadioglu, A ^b   O'Callaghan, C ^b   Andrew, P W ^b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b NONE

Author keywords

Cytokines; Meningitis; Pneumolysin; Pneumoniae; Septicaemia

Indexed keywords

PNEUMOLYSIN;

ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BLOOD BRAIN BARRIER; BRONCHOPNEUMONIA; CEREBROSPINAL FLUID; HUMAN; LOBAR PNEUMONIA; MENINGITIS; NASOPHARYNX; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEPTICEMIA; STREPTOCOCCUS PNEUMONIAE;

BACTEREMIA; BACTERIAL PROTEINS; CYTOKINES; HUMANS; MENINGITIS, PNEUMOCOCCAL; MODELS, IMMUNOLOGICAL; NEUTROPHILS; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE; STREPTOLYSINS; T-LYMPHOCYTES;

EID: 8144228074     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2004.02611.x     Document Type: Review

References (72)

1. Kalin M, Kanclerski K, Granstrom M, Mollby R. Diagnosis of pneumococcal pneumonia by enzyme-linked immunosorbent assay of antibodies to pneumococcal hemolysin (pneumolysin). J Clin Microbiol 1987; 25:226-9.
2. Andrew PW, Mitchell TJ, Morgan PJ. Relationship of structure to function in pneumolysin. Microb Drug Resist 1997; 3:11-7.
3. Gilbert RJ, Jimenez JL, Chen S et al. Two structural transitions in membrane pore formation by pneumolysin, the pore-forming toxin of Streptococcus pneumoniae. Cell 1999; 97:647-55.
4. Boulnois GJ, Paton JC, Mitchell TJ, Andrew PW. Structure and function of pneumolysin, the multifunctional, thiol-activated toxin of Streptococcus pneumoniae. Mol Microbiol 1991; 5:2611-6.
5. 2 mediate brain cell apoptosis during meningitis. J Clin Invest 2002; 109:19-27.
6. Mitchell TJ, Andrew PW, Saunders FK, Smith AN, Boulnois GJ. Complement activation and antibody binding by pneumolysin via a region of the toxin homologous to a human acute-phase protein. Mol Microbiol 1991; 5:1883-8.
7. Cockeran R, Theron AJ, Steel HC et al. Proinflammatory interactions of pneumolysin with human neutrophils. J Infect Dis 2001; 183:604-11.
8. Lopez R, Garcia E, Garcia P, Garcia JL. The pneumococcal cell wall degrading enzymes: a modular design to create new lysins? Microb Drug Resist 1997; 3:199-211.
9. Walker JA, Allen RL, Falmagne P, Johnson MK, Boulnois GJ. Molecular cloning, characterization, and complete nucleotide sequence of the gene for pneumolysin, the sulfhydryl-activated toxin of Streptococcus pneumoniae. Infect Immun 1987; 55:1184-9.
10. Berry AM, Yother J, Briles DE, Hansman D, Paton JC. Reduced virulence of a defined pneumolysin-negative mutant of Streptococcus pneumoniae. Infect Immun 1989; 57:2037-42.
11. Hirst RA, Sikand KS, Rutman A, Mitchell TJ, Andrew PW, O'Callaghan C. Relative roles of pneumolysin and hydrogen peroxide from Streptococcus pneumoniae in inhibition of ependymal ciliary beat frequency. Infect Immun 2000; 68:1557-62.
12. Hirst RA, Rutman A, Sikand K, Andrew PW, Mitchell TJ, O'Callaghan C. Effect of pneumolysin on rat brain ciliary function: comparison of brain slices with cultured ependymal cells. Pediatr Res 2000; 47:381-4.
13. Mohammed BJ, Mitchell TJ, Andrew PW, Hirst RA, O'Callaghan C. The effect of the pneumococcal toxin, pneumolysin on brain ependymal cilia. Microb Pathog 1999; 27:303-9.
14. Rubins JB, Duane PG, Clawson D, Charboneau D, Young J, Niewoehner DE. Toxicity of pneumolysin to pulmonary alveolar epithelial cells. Infect Immun 1993; 61:1352-8.
15. Cohen B, Halbert SP, Perkins ME. Pneumococcal hemolysin. The preparation of concentrates, and their action on red cells. J Bacteriol 1942; 43:607-27.
16. Halbert SP, Cohen B, Perkins ME. Toxic and immunological properties of pneumococcal hemolysin. Bull Johns Hopkins Hospital; 78:340-59.
17. Kreger AS, Bernheimer AW. Physical behavior of pneumolysin. J Bacteriol 1969; 98:306-7.
18. Paton JC, Lock RA, Hansman DJ. Effect of immunization with pneumolysin on survival time of mice challenged with Streptococcus pneumoniae. Infect Immun 1983; 40:548-52.
19. Paton JC, Berry AM, Lock RA, Hansman D, Manning PA. Cloning and expression in Escherichia coli of the Streptococcus pneumoniae gene encoding pneumolysin. Infect Immun 1986; 54:50-5.
20. Alexander JE, Lock RA, Peeters CC et al. Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae. Infect Immun 1994; 62:5683-8.
21. Berry AM, Paton JC, Hansman D. Effect of insertional inactivation of the genes encoding pneumolysin and autolysin on the virulence of Streptococcus pneumoniae type 3. Microb Pathog 1992; 12:87-93.
22. Hill J, Andrew PW, Mitchell TJ. Amino acids in pneumolysin important for hemolytic activity identified by random mutagenesis. Infect Immun 1994; 62:757-8.
23. Baba H, Kawamura I, Kohda C et al. Induction of gamma interferon and nitric oxide by truncated pneumolysin that lacks pore-forming activity. Infect Immun 2002; 70:107-13.
24. Berry AM, Alexander JE, Mitchell TJ, Andrew PW, Hansman D, Paton JC. Effect of defined point mutations in the pneumolysin gene on the virulence of Streptococcus pneumoniae. Infect Immun 1995; 63:1969-74.
25. Jounblat R, Kadioglu A, Mitchell TJ, Andrew PW. Pneumococcal behavior and host responses during bronchopneumonia are affected differently by the cytolytic and complement-activating activities of pneumolysin. Infect Immun 2003; 71:1813-9.
26. Canvin JR, Marvin AP, Sivakumaran M et al. The role of pneumolysin and autolysin in the pathology of pneumonia and septicemia in mice infected with a type 2 pneumococcus. J Infect Dis 1995; 172:119-23.
27. Rubins JB, Charboneau D, Paton JC, Mitchell TJ, Andrew PW, Janoff EN. Dual function of pneumolysin in the early pathogenesis of murine pneumococcal pneumonia. J Clin Invest 1995; 95:142-50.
28. Benton KA, Everson MP, Briles DE. A pneumolysin-negative mutant of Streptococcus pneumoniae causes chronic bacteremia rather than acute sepsis in mice. Infect Immun 1995; 63:448-55.
29. Kadioglu A, Taylor S, Iannelli F, Pozzi G, Mitchell TJ, Andrew PW. Upper and lower respiratory tract infection by Streptococcus pneumoniae is affected by pneumolysin deficiency and differences in capsule type. Infect Immun 2002; 70:2886-90.
30. Rubins JB, Paddock AH, Charboneau D, Berry AM, Paton JC, Janoff EN. Pneumolysin in pneumococcal adherence and colonization. Microb Pathog 1998; 25:337-42.
31. Houldsworth S, Andrew PW, Mitchell TJ. Pneumolysin stimulates production of tumor necrosis factor alpha and interleukin-1 beta by human mononuclear phagocytes. Infect Immun 1994; 62:1501-3.
32. Benton KA, VanCott JL, Briles DE. Role of tumor necrosis factor alpha in the host response of mice to bacteremia caused by pneumolysin-deficient Streptococcus pneumoniae. Infect Immun 1998; 66:839-42.
33. van der Poll T, Marchant A, Keogh CV, Goldman M, Lowry SF. Interleukin-10 impairs host defense in murine pneumococcal pneumonia. J Infect Dis 1996; 174:994-1000.
34. van der Poll T, Keogh CV, Guirao X, Buurman WA, Kopf M, Lowry SF. Interleukin-6 gene-deficient mice show impaired defense against pneumococcal pneumonia. J Infect Dis 1997; 176:439-44.
35. Kerr AR, Irvine JJ, Search JJ et al. Role of inflammatory mediators in resistance and susceptibility to pneumococcal infection. Infect Immun 2002; 70:1547-57.
36. O'Brien DP, Briles DE, Szalai AJ, Tu AH, Sanz I, Nahm MH. Tumor necrosis factor alpha receptor I is important for survival from Streptococcus pneumoniae infections. Infect Immun 1999; 67:595-601.
37. Gingles NA, Alexander JE, Kadioglu A et al. Role of genetic resistance in invasive pneumococcal infection: identification and study of susceptibility and resistance in inbred mouse strains. Infect Immun 2001; 69:426-34.
38. Gunn FD, Nungester WJ. Pathogenesis and histopathology of experimental pneumonia in rats. Arch Pathol 1936; 21:813-30.
39. Robertson OH, Coggeshall LT, Terrell EE. Experimental pneumococcus lobar pneumonia in the dog. II. Pathology. J Clin Invest 1933; 12:433-66.
40. Terrell EE, Robertson OH, Coggeshall LT. Experimental pneumococcus lobar pneumonia in the dog. I. Method of production and course of the disease. J Clin Invest 1933; 12:393-432.
41. Loosli CG, Baker RF. Acute experimental pneumococcal (type I) pneumonia in the mouse: the migration of leukocytes from the pulmonary capillaries into the alveolar spaces as revealed by the electron microscope. Trans Am Clin Climatol Assoc 1962; 74:15-28.
42. Garvy BA, Harmsen AG. The importance of neutrophils in resistance to pneumococcal pneumonia in adult and neonatal mice. Inflammation 1996; 20:499-512.
43. Bergeron Y, Ouellet N, Deslauriers AM, Simard M, Olivier M, Bergeron MG. Cytokine kinetics and other host factors in response to pneumococcal pulmonary infection in mice. Infect Immun 1998; 66:912-22.
44. Kadioglu A, Gingles NA, Grattan K, Kerr A, Mitchell TJ, Andrew PW. Host cellular immune response to pneumococcal lung infection in mice. Infect Immun 2000; 68:492-501.
45. Cockeran R, Durandt C, Feldman C, Mitchell TJ, Anderson R. Pneumolysin activates the synthesis and release of interleukin-8 by human neutrophils in vitro. J Infect Dis 2002; 186:562-5.
46. Nandoskar M, Ferrante A, Bates EJ, Hurst N, Paton JC. Inhibition of human monocyte respiratory burst, degranulation, phospholipid methylation and bactericidal activity by pneumolysin. Immunology 1986; 59:515-20.
47. Alexander JE, Berry AM, Paton JC, Rubins JB, Andrew PW, Mitchell TJ. Amino acid changes affecting the activity of pneumolysin alter the behaviour of pneumococci in pneumonia. Microb Pathog 1998; 24:167-74.
48. Kadioglu A, Coward W, Colston MJ, Hewitt CR, Andrew PW. CD4-T-lymphocyte interactions with pneumolysin and pneumococci suggest a crucial protective role in the host response to pneumococcal infection. Infect Immun 2004; 72:2689-97.
49. Yoshimura A, Lien E, Ingalls RR, Tuomanen E, Dziarski R, Golenbock D. Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J Immunol 1999; 163:1-5.
50. Malley R, Henneke P, Morse SC et al. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci USA 2003; 100:1966-71.
51. Bohr V, Paulson OB, Rasmussen N. Pneumococcal meningitis. Late neurologic sequelae and features of prognostic impact. Arch Neurol 1984; 41:1045-9.
52. Cairns H, Russell DS. Cerebral arteritis and phlebitis in pneumococcal meningitis. J Pathol Bacteriol 1946; 58:646-65.
53. Tureen JH, Dworkin RJ. Kennedy SL, Sachdeva M, Sande MA. Loss of cerebrovascular autoregulation in experimental meningitis in rabbits. J Clin Invest 1990; 85:577-81.
54. Tauber MG, Khayam-Bashi H, Sande MA. Effects of ampicillin and corticosteroids on brain water content, cerebrospinal fluid pressure, and cerebrospinal fluid lactate levels in experimental pneumococcal meningitis. J Infect Dis 1985; 151:528-34.
55. Scheld WM, Dacey RG, Winn HR, Welsh JE, Jane JA, Sande MA. Cerebrospinal fluid outflow resistance in rabbits with experimental meningitis. Alterations with penicillin and methylprednisolone. J Clin Invest 1980; 66:243-53.
56. Odio CM, Faingezicht I, Paris M et al. The beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis. N Engl J Med 1991; 324:1525-31.
57. Van Ginkel FW, McGhee JR, Watt JM, Campos-Torres A, Parish LA, Briles DE. Pneumococcal carriage results in ganglioside-mediated olfactory tissue infection. Proc Natl Acad Sci USA 2003; 100:14363-7.
58. Leib SL, Kim YS, Chow LL, Sheldon RA, Tauber MG. Reactive oxygen intermediates contribute to necrotic and apoptotic neuronal injury in an infant rat model of bacterial meningitis due to group B streptococci. J Clin Invest 1996; 98:2632-9.
59. Nau R, Bruck W. Neuronal injury in bacterial meningitis: mechanisms and implications for therapy. Trends Neurosci 2002; 25:38-45.
60. Scheld WM, Koedel U, Nathan B, Pfister HW. Pathophysiology of bacterial meningitis: mechanism(s) of neuronal injury. J Infect Dis 2002; 186 (Suppl. 2):S225-33.
61. Friedland IR, Paris MM, Hickey S et al. The limited role of pneumolysin in the pathogenesis of pneumococcal meningitis. J Infect Dis 1995; 172:805-9.
62. Wellmer A, Zysk G, Gerber J et al. Decreased virulence of a pneumolysin-deficient strain of Streptococcus pneumoniae in murine meningitis. Infect Immun 2002; 70:6504-8.
63. Wellmer A, Noeske C, Gerber J, Munzel U, Nau R. Spatial memory and learning deficits after experimental pneumococcal meningitis in mice. Neurosci Lett 2000; 296:137-40.
64. Zysk G, Schneider-Wald BK, Hwang JH et al. Pneumolysin is the main inducer of cytotoxicity to brain microvascular endothelial cells caused by Streptococcus pneumoniae. Infect Immun 2001; 69:845-52.
65. Hirst RA, Gosai B, Rutman A, Andrew PW, O'Callaghan C. Streptococcus pneumoniae damages the ciliated ependyma of the brain during meningitis. Infect Immun 2003; 71:6095-100.
66. Paton JC, Ferrante A. Inhibition of human polymorphonuclear leukocyte respiratory burst, bactericidal activity, and migration by pneumolysin. Infect Immun 1983; 41:1212-6.
67. Ferrante A, Rowan-Kelly B, Paton JC. Inhibition of in vitro human lymphocyte response by the pneumococcal toxin pneumolysin. Infect Immun 1984; 46:585-9.
68. Mitchell TJ, Walker JA, Saunders FK, Andrew PW, Boulnois GJ. Expression of the pneumolysin gene in Escherichia coli: rapid purification and biological properties. Biochim Biophys Acta 1989; 1007:67-72.
69. Feldman C, Mitchell TJ, Andrew PW et al. The effect of Streptococcus pneumoniae pneumolysin on human respiratory epithelium in vitro. Microb Pathog 1990; 9:275-84.
70. Rubins JB, Mitchell TJ, Andrew PW, Niewoehner DE. Pneumolysin activates phospholipase A in pulmonary artery endothelial cells. Infect Immun 1994; 62:3829-36.
71. Rayner CF, Jackson AD, Rutman A et al. Interaction of pneumolysin-sufficient and -deficient isogenic variants of Streptococcus pneumoniae with human respiratory mucosa. Infect Immun 1995; 63:442-7.
72. Braun JS, Novak R, Gao G, Murray PJ, Shenep JL. Pneumolysin, a protein toxin of Streptococcus pneumoniae, induces nitric oxide production from macrophages. Infect Immun 1999; 67:3750-6.